<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202965</url>
  </required_header>
  <id_info>
    <org_study_id>PTG-300-06</org_study_id>
    <nct_id>NCT04202965</nct_id>
  </id_info>
  <brief_title>PTG-300 in Subjects With Hereditary Hemochromatosis</brief_title>
  <official_title>Open-label Study of PTG-300 in Subjects With Hereditary Hemochromatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protagonist Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protagonist Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted at multiple sites and every patient will get treated with
      PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult
      hereditary hemochromatosis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, open-label study. The objective of the study is to assess the
      effect of PTG-300 on transferrin saturation (TSAT) and serum iron in adult hereditary
      hemochromatosis patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Arm Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of PTG-300 on Transferrin Saturation</measure>
    <time_frame>Week 24</time_frame>
    <description>Change in transferrin saturation (TSAT) as measured by blood laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of PTG-300 on Serum Iron</measure>
    <time_frame>Week 24</time_frame>
    <description>Change in serum iron as measured by blood laboratory tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of PTG-300 on Phlebotomy Frequency</measure>
    <time_frame>Week 24</time_frame>
    <description>Change in phlebotomy frequency as measured by number of phlebotomies over a 24 week period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>Week 24</time_frame>
    <description>The SF-36 is a participant-reported outcome measure. The instrument includes 36 items in a Likert-type format to measure the following health dimensions over the past week: limitations in physical activities; limitations in social activities; limitations in usual role activities; bodily pain; general mental health; vitality; and general health perceptions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Hereditary Hemochromatosis</condition>
  <arm_group>
    <arm_group_label>PTG-300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTG-300 Subcutaneous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTG-300</intervention_name>
    <description>Active treatment with PTG-300 subcutaneously</description>
    <arm_group_label>PTG-300</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 and older

          -  Confirmed diagnosis of HFE-related hereditary hemochromatosis with prior genotype
             testing

          -  Documented stable phlebotomy for ≥ 6 months

          -  Screening hemoglobin &gt;11.5 g/dL

          -  Documented evidence of prior serum ferritin ≥500 ng/mL

          -  Serum ferritin &gt;50 ng/mL and &lt;300 ng/mL at screening

        Exclusion Criteria:

          -  Clinically meaningful laboratory abnormality

          -  Receiving iron chelation therapy

          -  Receiving erythrocytapheresis

          -  Pregnant or lactating females

          -  Infection requiring hospitalization or intravenous antimicrobial therapy, or
             opportunistic infection within 3 months of dosing; any infections requiring
             antimicrobial therapy within 4 weeks of dosing.

          -  Serious or unstable medical or psychiatric condition that would prevent subject
             providing informed consent

          -  Organ damage from iron overload

          -  Primary or secondary immunodeficiency

          -  Positive hepatitis B or hepatitis C or known human immunodeficiency virus infection

          -  Known history of autoimmune/inflammatory diseases

          -  Any surgical procedures requiring general anesthesia within 1 month prior to screening
             or planned surgery during study

          -  History of invasive malignancies within last 2 years, except non-malignant skin cancer
             and local cured prostrate cancer, cervical cancer, or ductal carcinoma in situ

          -  Receipt of an investigational agent within 30 days of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>1-888-899-1543</phone>
    <email>ptgxclintrials@ptgx-inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Protagonist Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>888-899-1543</phone>
      <email>ptgxclintrials@ptgx-inc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Protagonist Investigational Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>888-899-1543</phone>
      <email>ptgxclintrials@ptgx-inc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Protagonist Investigational Site</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Protagonist Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Protagonist Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Protagonist Therapeutics, Inc.</last_name>
      <phone>1-888-899-1543</phone>
      <email>ptgxclintrials@ptgx-inc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemochromatosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

